Residual Tumor Volume and Tumor Progression after Subtotal Resection and Observation of WHO Grade I Skull Base Meningiomas

Abstract

Objective This study investigated the impact of residual tumor volume (RTV) on tumor progression after subtotal resection and observation of WHO grade I skull base meningiomas.

Study Design This study is a retrospective volumetric analysis.

Setting This study was conducted at a single institution.

Participants Patients who underwent subtotal resection of a WHO grade I skull base meningioma and postsurgical observation (July 1, 2007–July 1, 2017).

Main Outcome Measure The main outcome was radiographic tumor progression.

Results Sixty patients with residual skull base meningiomas were analyzed. The median (interquartile range) RTV was 1.3 (5.3) cm³. Tumor progression occurred in 23 patients (38.3%) at a mean duration of 28.6 months postsurgery. The 1-, 3-, and 5-year actuarial progression-free survival (PFS) rates were 98.3, 58.6, and 48.7%, respectively. The Cox multivariate analysis identified increasing RTV (p = 0.01) and history of more than 1 previous surgery (p = 0.03) as independent predictors of tumor progression. In a Kaplan–Meier analysis for PFS, the RTV threshold of 3 cm³ maximized log-rank testing significance between groups of patients dichotomized at 0.5 cm³ thresholds (p < 0.01). The 3-year actuarial PFS rates for meningiomas with RTV ≤3 cm³ and >3 cm³ were 76.2 and 32.1%, respectively. When RTV >3 cm³ was entered as a covariate in the Cox model, it was the only factor independently associated with tumor progression (p < 0.01).

Conclusion RTV was associated with tumor progression after subtotal resection of WHO grade I skull base meningioma in this cohort. An RTV threshold of 3 cm³ was identified that minimized progression of the residual tumor when gross total resection was not safe or feasible.

Keywords

meningioma - progression - recurrence - residual - skull base - tumor

Publikationsverlauf

Eingereicht: 25. Februar 2021

Angenommen: 09. Juli 2021

Artikel online veröffentlicht:
09. September 2021

• References

• 1 Przybylowski CJ, Hendricks BK, Frisoli FA. et al. Prognostic value of the Simpson grading scale in modern meningioma surgery: Barrow Neurological Institute experience. J Neurosurg 2020; 1-9
• 2 Nanda A, Bir SC, Maiti TK, Konar SK, Missios S, Guthikonda B. Relevance of Simpson grading system and recurrence-free survival after surgery for World Health Organization grade I meningioma. J Neurosurg 2017; 126 (01) 201-211
• 3 Winther TL, Torp SH. Significance of the extent of resection in modern neurosurgical practice of World Health Organization grade I meningiomas. World Neurosurg 2017; 99: 104-110
• 4 Materi J, Mampre D, Ehresman J, Rincon-Torroella J, Chaichana KL. Predictors of recurrence and high growth rate of residual meningiomas after subtotal resection. J Neurosurg 2020; 1-7
• 5 Youngblood MW, Duran D, Montejo JD. et al. Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas. J Neurosurg 2019; 1-10
• 6 Ichinose T, Goto T, Ishibashi K, Takami T, Ohata K. The role of radical microsurgical resection in multimodal treatment for skull base meningioma. J Neurosurg 2010; 113 (05) 1072-1078
• 7 Louis DN, Ohgaki H, Wiestler OD. et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114 (02) 97-109
• 8 Louis DN, Perry A, Reifenberger G. et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016; 131 (06) 803-820
• 9 Fukushima Y, Oya S, Nakatomi H. et al. Effect of dural detachment on long-term tumor control for meningiomas treated using Simpson grade IV resection. J Neurosurg 2013; 119 (06) 1373-1379
• 10 Oya S, Kawai K, Nakatomi H, Saito N. Significance of Simpson grading system in modern meningioma surgery: integration of the grade with MIB-1 labeling index as a key to predict the recurrence of WHO grade I meningiomas. J Neurosurg 2012; 117 (01) 121-128
• 11 Zador Z, Landry AP, Balas M, Cusimano MD. Landscape of immune cell gene expression is unique in predominantly WHO grade 1 skull base meningiomas when compared to convexity. Sci Rep 2020; 10 (01) 9065
• 12 Yesilöz Ü, Kirches E, Hartmann C. et al. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence. Neuro-oncol 2017; 19 (08) 1088-1096
• 13 Savardekar AR, Patra DP, Bir S. et al. Differential tumor progression patterns in skull base versus non-skull base meningiomas: a critical analysis from a long-term follow-up study and review of literature. World Neurosurg 2018; 112: e74-e83
• 14 Hashimoto N, Rabo CS, Okita Y. et al. Slower growth of skull base meningiomas compared with non-skull base meningiomas based on volumetric and biological studies. J Neurosurg 2012; 116 (03) 574-580
• 15 Mansouri A, Klironomos G, Taslimi S. et al. Surgically resected skull base meningiomas demonstrate a divergent postoperative recurrence pattern compared with non-skull base meningiomas. J Neurosurg 2016; 125 (02) 431-440
• 16 Sahm F, Schrimpf D, Stichel D. et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol 2017; 18 (05) 682-694
• 17 Clark VE, Erson-Omay EZ, Serin A. et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013; 339 (6123): 1077-1080